China's Surgical Robotics Industry in 2026: Why It Matters to the World

Why Global MedTech Companies Are Watching China

China has become one of the most active environments for developing and commercializing surgical robotic systems. Domestic companies are competing across laparoscopic, orthopedic, neurosurgical, dental and other specialties, while established international manufacturers continue to serve Chinese hospitals.

The industry's importance comes from its breadth of product development, diversity of commercial models and growing international activity. It does not follow that China already leads the world in accumulated robotic procedures, installed base or clinical outcomes; those are separate measures, and global incumbents retain substantial advantages in mature markets.

MedRobot, the surgical robotics publication within the Siyu MedTech network, has tracked public procurement results and supplemented them with manufacturer disclosures and industry submissions. Its research helps international readers distinguish real transactions from product announcements.

Three Numbers, With Essential Definitions

2024: at least 313 recorded units. MedRobot's original report used a composite scope that included public procurement, reported system sales and certain overseas orders. The figure should not be read as domestic installations alone.

2025: at least 611 systems. The following year's research identified a materially larger combined volume.

First half of 2026: at least 366 systems. MedRobot's interim study documented activity across multiple specialties and reported a significant overseas contribution from certain Chinese laparoscopic robot manufacturers.

These numbers must be read with care. The datasets include sales in mainland China and overseas sales or deliveries by Chinese manufacturers, according to the applicable methodology. They are not counts of newly installed robots inside China alone, nor are they the total number of surgeries performed. Manufacturer-reported information can also differ in completeness from public hospital tender data. Half-year results should not simply be doubled to predict a full-year outcome.

For source tables and methodology, see MedChina's 2025 China Surgical Robot Sales Annual Report and H1 2026 MedRobot Industry Landscape Analysis.

An Industry Wider Than Laparoscopic Surgery

Laparoscopic Surgery

Laparoscopic robots remain the best-known category. Chinese developers have launched multiport and single-port systems and are investing in imaging, instruments, energy integration and teleoperation. Important manufacturers to follow include MicroPort MedBot, Edge Medical, Sagebot, Cornerstone Robotics and other domestic developers, alongside established international competitors.

MedRobot counted at least 229 laparoscopic systems within its 2025 annual statistical scope. The H1 2026 report found at least 191 endoscopic surgical robot systems, with a striking feature: overseas shipments from a small number of Chinese manufacturers accounted for a substantial proportion of the reported total.

That distinction is important. A high combined sales number for Chinese manufacturers does not necessarily indicate an equally high level of new installation activity within Chinese hospitals.

Orthopedic Surgery

China's orthopedic robotics activity spans spine, joint replacement and trauma applications. The segment combines established developers such as TINAVI with a growing group of companies offering different levels of automated execution, robotic positioning and integrated surgical planning.

MedRobot reported at least 168 orthopedic systems under its 2025 combined methodology, and 19 participating manufacturers in the H1 2026 orthopedic segment. Differences in procedure selection, implant compatibility, imaging requirements and service arrangements make this a highly differentiated market.

Not every device described commercially as a "robot" has a surgical robotic arm. MedRobot's surgical robot research excludes pure navigation systems from its robotic-system sales counts, so cross-company comparisons need to check product definitions.

Neurosurgery, Dentistry and Emerging Procedures

Neurosurgical robots support specialized stereotactic and related workflows. Dental implant robots are also gaining commercial traction across public hospitals, private dental institutions and selected overseas markets.

Robotic systems for natural-orifice surgery, percutaneous intervention and selected vascular procedures remain much earlier in commercialization. These categories should be analyzed separately from mature laparoscopic platforms. A regulatory approval, clinical demonstration and commercial system sale represent different stages of adoption.

What Public Hospital Procurement Reveals

Sales and delivery reports give one perspective; publicly announced hospital awards provide another. For the first half of 2026, MedRobot identified 27 public-hospital procurement awards for endoscopic surgical robotic systems in mainland China. Seventeen were awarded to domestic brands, representing approximately 63% of the total in this specific public-tender dataset.

This is evidence of domestic competition in new public-hospital purchasing. It is not a 63% figure for China's total installed base, private hospitals, procedure volume or combined international sales.

Tender records can also show award prices, product configurations, hospitals and purchasing cycles. These details help explain where particular robotic technologies are being adopted and how hospital demand is changing.

Regulation Is Creating a Larger Product Landscape

China's NMPA has approved a growing variety of surgical robotic systems and indication expansions. MedChina's 2025 approval review counted 52 relevant approval events for Chinese surgical robotics, encompassing newly registered systems and new clinical indications within its stated definition. The figure should not be described as 52 entirely new robot models.

Commercial maturity must also be assessed independently from regulatory status. A newly approved product may have a narrow indication, limited production capacity or a small number of trained clinical teams. Expansion of an existing product's intended use may be commercially significant even when it is not a new system launch.

The Commercial Challenge: From Equipment to Repeatable Procedures

Surgical robotics requires substantial investment after product development. Hospitals consider system purchase cost, maintenance, instruments, sterilization workflows, room utilization, physician training and the economics of each procedure. Manufacturers must provide field service, software support and replacement instruments over the equipment's lifecycle.

China is experimenting with direct purchases, financing and service-linked models. Payment policy is also evolving. In January 2026, the National Healthcare Security Administration issued national guidance for pricing several forms of robotic surgical assistance, with categories linked to the robot's contribution to the underlying operation. Provincial implementation and actual insurance coverage remain distinct questions.

These factors influence which robotic platforms can achieve sustained use beyond initial installation.

October 28, 2026

Chinese Surgical Robots Are Increasingly an International Question

The H1 2026 MedRobot dataset reported that three Chinese endoscopic robot manufacturers — MicroPort MedBot, Sagebot and Cornerstone Robotics — collectively recorded more than 154 overseas system shipments within the reported period. The overseas total was concentrated among a few companies, so it should not be generalized to every manufacturer.

For international hospitals and distributors, a device's country of origin is only one consideration. Local regulatory authorization, procedure-specific clinical evidence, training, instrument supply, service response and the stability of the manufacturer determine whether a system can be used safely and economically.

For international manufacturers, the competitive significance of China is now visible in product development, domestic hospital procurement and overseas commercialization. Its long-term standing will be determined by repeatable clinical results and operating performance, not by the number of companies announcing robotic systems.